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Therapy for Prevention of
Contrast-Induced Nephropathy
How to Give More Without Causing Heart Failure*Richard Solomon, MDI odinated contrast media is widely used toenhance the image of organs and the vascularcompartment. In a small percentage of patients,
the administration of contrast is followed by a
decrease in glomerular ﬁltration rate (GFR), referred
to as contrast-induced nephropathy (CIN). The fall in
GFR is detected by a rise in serum creatinine evident
within 48 to 72 h of contrast exposure. The decrement
in GFR is usually transient, and serum creatinine
returns to or near baseline levels within 7 to 10 days.
CIN is, nevertheless, associated with in-hospital mor-
tality and adverse events (1), long-term mortality (2),
progression of kidney disease (3), long-term major
adverse cardiovascular events (4), and reduced use of
cardiovascular preventative medications (5).SEE PAGE 89The mechanism of CIN is multifactorial and in-
cludes regional hemodynamic changes (6) as well as
direct renal tubule cell toxicity (7). Patients at risk for
CIN are usually older, receive more contrast, and have
underlying compromised kidney and vascular func-
tion (chronic kidney disease, diabetes, heart failure).
The setting in which contrast is administered is also
important, with higher rates of CIN occurring with*Editorials published in JACC: Cardiovascular Interventions reﬂect the
views of the authors and do not necessarily represent the views of JACC:
Cardiovascular Interventions or the American College of Cardiology.
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modynamically compromised patients.
Preventative strategies for CIN can be employed
because administration of contrast is a known event.
A number of approaches to CIN prevention have been
subjected to prospective randomized trials. The ma-
jority of these trials have been conducted in high-risk
patients undergoing coronary angiography with or
without a percutaneous coronary intervention.
The mainstay of preventative therapy is reduction
in the amount of contrast administered. Additionally,
intravenous (IV) administration of isotonic ﬂuids
before, during, and after contrast exposure is also
considered standard of care. Potential mechanisms for
the beneﬁt of IV ﬂuids include reductions in systemic
and regional vasoconstrictor forces, improvement in
tissue resistance to reactive oxygen species (8), and
enhanced washout of contrast through the kidney.
This latter effect is supported by observational data
that the incidence of CIN is reduced with higher urine
ﬂow rate (9–11). Because increasing urine ﬂow itself
does not increase GFR and contrast clearance, it is
assumed that the concentration of contrast within the
tubule lumen is diminished and transient time
through the nephron is increased by these high urine
ﬂow rates. This would mitigate the exposure of renal
tubule cells to the direct toxic effects of the contrast.
It would thus make intuitive sense to just give as
much isotonic ﬂuid as possible to minimize the toxic
effects of contrast and create enough volume expan-
sion to turn down vasoconstrictor tone. Unfortu-
nately, too much ﬂuid can have a deleterious effect,
particularly in patients with underlying impaired
cardiac function, by provoking acute decompensated
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98heart failure (ADHF). It is this goal to achieve efﬁcacy
without sacriﬁce of safety that drives attempts to ﬁnd
novel ways to guide therapy.
POSEIDON (Prevention of Contrast Renal Injury
with Different Hydration Strategies) used left ven-
tricular end-diastolic pressure (LVEDP) obtained
before any contrast was given to determine a rate of
IV ﬂuid administration during and after the angiog-
raphy. Compared with patients randomized to stan-
dard of care, patients randomized to IV ﬂuid on the
basis of LVEDP received twice as much ﬂuid. The
incidence of CIN was reduced in those patients (6.7%
vs. 16.3%, relative risk: 0.41; p ¼ 0.005) (12).
Two trials used a forced diuresis system
(RenalGuard, Milford, Massachusetts) with IV ﬂuid
administration matching urine output drop by drop in
real time. High urine outputs (300 to 600 ml/h) were
achieved without a risk of ADHF. Both trials found
a lower incidence of CIN with the RenalGuard
device (9,10).
In this issue of JACC: Cardiovascular Interventions,
investigators from China describe a strategy using
dynamic central venous pressure (CVP) to guide the
amount of IV isotonic saline administered before,
during, and after coronary angiography (13). In
a double-blind, randomized prospective trial, 264
patients were given 0.9% NaCl starting 6 h before the
procedure and continuing for 12 h after the proce-
dure. Patients were at high risk for CIN by virtue of a
history of symptomatic ADHF, left ventricular ejection
fraction <50%, and chronic kidney disease with esti-
mated glomerular ﬁltration rate 15 to 60 ml/min/1.73 m2.
The control group received 1 ml/min/h for the entire
period (approximately 18 h). In the dynamic CVP
group, the rate was adjusted hourly depending upon
the CVP. The 2 groups were well matched for age,
baseline left ventricular ejection fraction, estimated
glomerular ﬁltration rate, CVP distribution, and
presence of diabetes. Percutaneous coronary inter-
vention was carried out in 85% and 90% of patients,
respectively, with an average contrast volume of 161
and 171 ml.As one might expect, the dynamic CVP group
received more IV ﬂuid (1,827 ml vs. 1,202 ml) and had
a greater urine volume (1,461 ml vs. 806 ml) during
the study period. This translated into a signiﬁcant
reduction in CIN by any deﬁnition (15.9% vs. 29.5%
using a deﬁnition of >25% and/or >0.5 mg/dl increase
in creatinine). There was no beneﬁt in the dynamic
CVP group when the initial CVP was >12 cmH2O, and
patients received the identical IV infusion rate as
control subjects. When analyzing all 264 patients as a
single group, the rate of CIN fell signiﬁcantly as the
amount of IV ﬂuid given increased. No patients
developed CIN who received >1,700 ml over the study
period.
The reduction in the incidence of CIN was also
associated with a reduction in 90-day major adverse
events. Only 9 patients required cessation of IV ﬂuid
for symptoms of ADHF (4 control, 5 CVP), and 52 pa-
tients in the CVP group required a reduction in IV
ﬂuid rate.
These results reafﬁrm the importance of giving as
much IV ﬂuid as possible for prevention of CIN. The
results also reafﬁrm indirectly the association of a
high urine ﬂow rate with a reduced risk of kidney
injury. Using CVP or LVEDP aids in maximizing the
amount of IV ﬂuid without risking ADHF. An alter-
native approach is forced diuresis using RenalGuard
that does not induce a change in extracellular
volume.
Despite these encouraging results, the incidence of
CIN has not dropped to zero, suggesting that mecha-
nisms unaffected by volume expansion or urine
output are contributing to kidney injury following
contrast administration. This creates space for addi-
tional novel therapies to be explored.
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